治疗寻常痤疮新药:clascoterone

A new drug in treatment of acne vulgaris: clascoterone

clascoterone是一种雄激素受体抑制剂,由意大利Cassiopea S.p.A.公司研发。clascoterone乳膏于2020年8月获美国食品和药物管理局批准,用于12岁及以上寻常痤疮患者的局部治疗。clascoterone具有较强的局部抗雄激素丙酸睾酮的作用,不表现系统性抗雄激素作用。1%clascoterone乳膏安全性与乳膏基质相似,常见的局部皮肤反应包括红斑/潮红、脱屑/干燥、皮肤瘙痒等。

Clascoterone is an androgen receptor inhibitor that developed by Italian Cassiopea S.p.A. In August 2020, clascoterone cream was approved by the U.S. Food and Drug Adiministration for the topical treatment of acne vulgaris in patients 12 years of age and older. Clascoterone endowed with strong local antiandrogenic activity against testosterone propionate,while absence of systemic antiandrogenic effects. Clascoterone cream 1% has been demonstrated a similar safety profile to that of vehicle, and common local skin reactions are erythema/redness, scaling/dryness, pruritus, and so on.